Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the 2014 RBC Capital Markets’ Global Healthcare Conference on Tuesday, February 25, 2014 at 8:00 a.m. EST at the New York Palace Hotel in New York City. Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock opened at $6.10 in last session, and closed at $6.18, while the day range of stock is $5.75 -$6.50. The stock showed a positive weekly performance of 40.45%.
At the IASLC 14thAnnual Targeted Therapies of the Treatment of Lung Cancer Meeting, which was held in Santa Monica, California, Synta Pharmaceuticals Corp (NASDAQ:SNTA) reported on advancement with lead compounds from its HDC platform. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) stock opened at $6.85, in last session and closed at $7.01, by gaining 8.85%. The 52 week range of the stock is $3.70 – $10.74. Company’s market capitalization is $484.44 million.
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) has recently released the results of its REACH2HD trial, which it has described as a success. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) stock advanced 12.45% and finished the last session at $9.03. The EPS of the stock remained -0.21. Company’s market capitalization is $367.89 million.
Stock analysts at Barclays started coverage on shares of Celladon Corp (NASDAQ:CLDN) in a report issued on Monday,AnalystRatingsNetwork.com reports. The firm set an “overweight” rating and a $15.00 price target on the stock. Celladon Corp (NASDAQ:CLDN) stock opened the session at $9.17, and closed the session at $9.50. The 52 week range of the stock remained $7.45 -$14.68 and the day range was $8.69 – $14.68.